Last reviewed · How we verify

Metformin + Testosterone Undecanoate

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Phase 3 active Small molecule

Metformin + Testosterone Undecanoate is a Combination therapy: biguanide + androgen replacement Small molecule drug developed by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. It is currently in Phase 3 development for Type 2 diabetes with hypogonadism, Metabolic syndrome with testosterone deficiency.

Metformin improves insulin sensitivity and glucose metabolism while testosterone undecanoate restores androgen levels, together addressing metabolic dysfunction and hypogonadism.

Metformin improves insulin sensitivity and glucose metabolism while testosterone undecanoate restores androgen levels, together addressing metabolic dysfunction and hypogonadism. Used for Type 2 diabetes with hypogonadism, Metabolic syndrome with testosterone deficiency.

At a glance

Generic nameMetformin + Testosterone Undecanoate
SponsorFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Drug classCombination therapy: biguanide + androgen replacement
TargetAMPK (metformin); androgen receptor (testosterone undecanoate)
ModalitySmall molecule
Therapeutic areaEndocrinology / Metabolic Disease
PhasePhase 3

Mechanism of action

Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity through AMPK activation and mitochondrial effects. Testosterone undecanoate is a long-acting androgen replacement that restores physiological testosterone levels. The combination targets both insulin resistance and testosterone deficiency, which often co-occur in metabolic syndrome and related conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Metformin + Testosterone Undecanoate

What is Metformin + Testosterone Undecanoate?

Metformin + Testosterone Undecanoate is a Combination therapy: biguanide + androgen replacement drug developed by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud, indicated for Type 2 diabetes with hypogonadism, Metabolic syndrome with testosterone deficiency.

How does Metformin + Testosterone Undecanoate work?

Metformin improves insulin sensitivity and glucose metabolism while testosterone undecanoate restores androgen levels, together addressing metabolic dysfunction and hypogonadism.

What is Metformin + Testosterone Undecanoate used for?

Metformin + Testosterone Undecanoate is indicated for Type 2 diabetes with hypogonadism, Metabolic syndrome with testosterone deficiency.

Who makes Metformin + Testosterone Undecanoate?

Metformin + Testosterone Undecanoate is developed by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (see full Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud pipeline at /company/fundaci-n-p-blica-andaluza-para-la-investigaci-n-de-m-laga-en-biomedicina-y-salu).

What drug class is Metformin + Testosterone Undecanoate in?

Metformin + Testosterone Undecanoate belongs to the Combination therapy: biguanide + androgen replacement class. See all Combination therapy: biguanide + androgen replacement drugs at /class/combination-therapy-biguanide-androgen-replacement.

What development phase is Metformin + Testosterone Undecanoate in?

Metformin + Testosterone Undecanoate is in Phase 3.

What are the side effects of Metformin + Testosterone Undecanoate?

Common side effects of Metformin + Testosterone Undecanoate include Gastrointestinal disturbance (metformin), Polycythemia (testosterone), Hepatotoxicity risk, Cardiovascular effects.

What does Metformin + Testosterone Undecanoate target?

Metformin + Testosterone Undecanoate targets AMPK (metformin); androgen receptor (testosterone undecanoate) and is a Combination therapy: biguanide + androgen replacement.

Related